| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 151, Issue 5 2380-2389, Copyright © 1993 by American Association of Immunologists
ARTICLES |
TM Ellis, PE Simms, DJ Slivnick, HM Jack and RI Fisher
Division of Hematology and Oncology, Loyola University Stritch School of Medicine, Maywood, IL 60153.
CD30 has been extensively studied as a cell surface marker expressed by Reed-Sternberg cells of Hodgkin's disease and other hematologic malignancies, although little is known about its expression by normal lymphoid cells. We therefore characterized the requirements for the induction of CD30 expression and identified the subsets of T cells that express CD30. CD30 is inducible on approximately 15% of normal PBMC stimulated with any of a variety of nonspecific T cell activators, including PHA, Con A, anti-T11(2) + T11(3), and anti-CD3; ionomycin alone induced lower percentages of CD30+ T cells (3 +/- 2%) compared to other stimuli. Maximal numbers of CD30+ cells were observed at 48 to 72 h of activation and the addition of rIL-2 did not affect these kinetics. However, CD30 expression was enhanced by the addition of exogenous rIL-2 to any of the stimuli tested, although rIL-2 alone did not lead to CD30 expression. The induction of CD30 during anti-CD3 mitogenesis was completely inhibitable by anti-IL-2 antibodies and partially inhibitable by rIL-4, indicating a requirement for both TCR triggering and IL-2 for its expression. Dual immunofluorescence analysis revealed that CD30+ cells were confined to CD3+ T cells that coexpressed higher levels of the p55 IL-2 receptor (CD25) than the CD30- population. Furthermore, CD30 expression was restricted to a subset of cells derived from CD45RO+ T cell precursors. Cell cycle analysis showed that CD30+ expression was not cell cycle dependent. Cross- linking of membrane CD30 induced Ca2+ in TCR+, but not TCR- Jurkat T cells. These results demonstrate that CD30 can serve as a T cell signal- transducing molecule and expressed by a unique subset of activated CD45RO+ T cells.
This article has been cited by other articles:
|
|
 |
|
  C. Tang, H. Yamada, K. Shibata, H. Muta, W. Wajjwalku, E. R. Podack, and Y. Yoshikai A Novel Role of CD30L/CD30 Signaling by T-T Cell Interaction in Th1 Response against Mycobacterial Infection J. Immunol., November 1, 2008; 181(9): 6316 - 6327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Nam, Y.-H. Kim, J.-S. Do, Y.-H. Choi, H.-J. Seo, H.-K. Yi, P.-H. Hwang, C.-H. Song, H.-K. Lee, J.-S. Kim, et al. CD30 supports lung inflammation Int. Immunol., February 1, 2008; 20(2): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nishimura, T. Yajima, H. Muta, E. R. Podack, K. Tani, and Y. Yoshikai A Novel Role of CD30/CD30 Ligand Signaling in the Generation of Long-Lived Memory CD8+ T Cells J. Immunol., October 1, 2005; 175(7): 4627 - 4634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gerli, C. Lunardi, and C. Pitzalis Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis Rheumatology, December 1, 2002; 41(12): 1341 - 1345. [Full Text] [PDF]
|
|
|
|
|
|
K. W. Chan, C. D. Hopke, S. M. Krams, and O. M. Martinez CD30 Expression Identifies the Predominant Proliferating T Lymphocyte Population in Human Alloimmune Responses J. Immunol., August 15, 2002; 169(4): 1784 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kemp, J. A. L. Kurtzhals, B. D. Akanmori, V. Adabayeri, B. Q. Goka, C. Behr, and L. Hviid Increased Levels of Soluble CD30 in Plasma of Patients with Plasmodium falciparum Malaria Clin. Vaccine Immunol., May 1, 2002; 9(3): 720 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vinante, A. Rigo, M. T. Scupoli, and G. Pizzolo CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540 Blood, January 1, 2002; 99(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Barbano, F. Cappa, I. Prigione, V. Pistoia, A. Cohen, S. Chiesa, R. Gusmano, and F. Perfumo Plasma levels of soluble CD30 are increased in children with chronic renal failure and with primary growth deficiency and decrease during treatment with recombination human growth hormone Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1807 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Seah and G. A. W. Rook IL-4 Influences Apoptosis of Mycobacterium-Reactive Lymphocytes in the Presence of TNF-{alpha} J. Immunol., August 1, 2001; 167(3): 1230 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Mir, B. W. M. Richter, and C. S. Duckett Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells Blood, December 15, 2000; 96(13): 4307 - 4312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Kadin Regulation of CD30 Antigen Expression and Its Potential Significance for Human Disease Am. J. Pathol., May 1, 2000; 156(5): 1479 - 1484. [Full Text] [PDF]
|
|
|
|
|
|
E. J. Croager, A. M. Gout, and L. J. Abraham Involvement of Sp1 and Microsatellite Repressor Sequences in the Transcriptional Control of the Human CD30 Gene Am. J. Pathol., May 1, 2000; 156(5): 1723 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gerli, C. Pitzalis, O. Bistoni, B. Falini, V. Costantini, A. Russano, and C. Lunardi CD30+ T Cells in Rheumatoid Synovitis: Mechanisms of Recruitment and Functional Role J. Immunol., April 15, 2000; 164(8): 4399 - 4407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Horie, V. Gattei, K. Ito, S. Imajo-Ohmi, T. Tange, J. Miyauchi, A. Pinto, M. Degan, A. De Iuliis, F. Tassan Mazzocco, et al. Frequent Expression of the Variant CD30 in Human Malignant Myeloid and Lymphoid Neoplasms Am. J. Pathol., December 1, 1999; 155(6): 2029 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mori, C. Manuelli, N. Pimpinelli, C. Mavilia, E. Maggi, M. Santucci, B. Bianchi, P. Cappugi, B. Giannotti, and M.E. Kadin CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+ T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression Blood, November 1, 1999; 94(9): 3077 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chiarle, A. Podda, G. Prolla, E. R. Podack, G. J. Thorbecke, and G. Inghirami CD30 Overexpression Enhances Negative Selection in the Thymus and Mediates Programmed Cell Death Via a Bcl-2-Sensitive Pathway J. Immunol., July 1, 1999; 163(1): 194 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jeannin, N. Herbault, Y. Delneste, G. Magistrelli, S. Lecoanet-Henchoz, G. Caron, J.-P. Aubry, and J.-Y. Bonnefoy Human Effector Memory T Cells Express CD86: A Functional Role in Naive T Cell Priming J. Immunol., February 15, 1999; 162(4): 2044 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamamoto, T. Kishimoto, and S. Minamoto NF-{kappa}B Activation in CD27 Signaling: Involvement of TNF Receptor-Associated Factors in Its Signaling and Identification of Functional Region of CD27 J. Immunol., November 1, 1998; 161(9): 4753 - 4759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Elewaut, F. De Keyser, N. De Wever, D. Baeten, N. Van Damme, G. Verbruggen, C. Cuvelier, and E. M Veys A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers Ann Rheum Dis, August 1, 1998; 57(8): 480 - 486. [Abstract] [Full Text]
|
|
|
|
|
|
M. C. Gilfillan, P. J. Noel, E. R. Podack, S. L. Reiner, and C. B. Thompson Expression of the Costimulatory Receptor CD30 Is Regulated by Both CD28 and Cytokines J. Immunol., March 1, 1998; 160(5): 2180 - 2187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Duckett and C. B. Thompson CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival Genes & Dev., November 1, 1997; 11(21): 2810 - 2821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gattei, M. Degan, A. Gloghini, A. De Iuliis, S. Improta, F. M. Rossi, D. Aldinucci, V. Perin, D. Serraino, R. Babare, et al. CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin Blood, March 15, 1997; 89(6): 2048 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Tsitsikov, D. A. Wright, and R. S. Geha CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2 PNAS, February 18, 1997; 94(4): 1390 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Aizawa, H. Nakano, T. Ishida, R. Horie, M. Nagai, K. Ito, H. Yagita, K. Okumura, J. Inoue, and T. Watanabe Tumor Necrosis Factor Receptor-associated Factor (TRAF) 5and TRAF2 Are Involved in CD30-mediated NFkappa B Activation J. Biol. Chem., January 24, 1997; 272(4): 2042 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ansieau, I. Scheffrahn, G. Mosialos, H. Brand, J. Duyster, K. Kaye, J. Harada, B. Dougall, G. Hubinger, E. Kieff, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation PNAS, November 26, 1996; 93(24): 14053 - 14058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Gedrich, M. C. Gilfillan, C. S. Duckett, J. L. Van Dongen, and C. B. Thompson CD30 Contains Two Binding Sites with Different Specificities for Members of the Tumor Necrosis Factor Receptor-associated Factor Family of Signal Transducing Proteins J. Biol. Chem., May 31, 1996; 271(22): 12852 - 12858. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
